S-1(DGS), nedaplatin, and cetuximab chemotherapy for advanced or recurrent head and neck cancer: a phase I/II study.

S-1(DGS), nedaplatin, and cetuximab chemotherapy for advanced or recurrent head and neck cancer: a phase I/II study. - S-1(DGS), nedaplatin, and cetuximab chemotherapy for advanced or recurrent head and neck cancer: a phase I/II study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017573

Enrollment

Registered

2015-05-15

Start date

2015-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent head and neck carcinoma

Interventions

S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over 20 age and under 80 age

Exclusion criteria

Exclusion criteria: drug allergy history

Design outcomes

Primary

Measure	Time frame
general condition tumor marker CT,MRI	—

Countries

Japan

Contacts

Public ContactRyuji Yasumatsu

Kyushu University Otorhinolaryngology

yasuryuj@qent.med.kyushu-u.ac.jp092-642-5668

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026